Fragile X Syndrome Clinical Trial
Official title:
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG
Individuals with Fragile X Syndrome show differences in how they understand and learn language from infancy. They frequently have lifelong delays in speech and language as well. In addition, they experience other auditory symptoms, including being very sensitive to certain sounds as well as being more sensitive than others to loud sounds. The underlying brain activity for sound perception and speech learning in Fragile X is not well understood, especially in the infant and toddler years. This study uses behavioral assessment of speech and language abilities, neuroimaging, and hearing tests to understand how speech and hearing are different in children with Fragile X Syndrome.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | August 31, 2027 |
Est. primary completion date | September 1, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Months to 5 Years |
Eligibility | Inclusion Criteria: - Diagnoses of Fragile X Syndrome, Typical Development, or History of Premature Birth - able to sit independently - English is spoken at home Exclusion Criteria: - For all participants: no seizures in the past 6 months - For typical development group and Fragile X group: not born prior to 36 weeks gestation |
Country | Name | City | State |
---|---|---|---|
United States | Cincinnati Children'S Hospital | Cincinnati | Ohio |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital Medical Center, Cincinnati |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Mullen Scales of Early Learning | change in Mullen Scales scores (age-corrected) from baseline on all subscales, including Expressive Language, Receptive Language, FIne Motor, Gross Motor, and Visual Reception. T-Scores from the Mullen Scales of Early Learning (MSEL) have a mean of 50 and a standard deviation of 10. Range=20-80. Higher scores indicate more advanced developmental skills. | at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits | |
Primary | Changes in oxygenated and deoxygenated hemoglobin concentration in response to sounds in language regions of the brain | Relative increase in oxygenated versus deoxygenated hemoglobin for no sounds, low intensity sounds, and medium intensity sounds. Measured via functional Near Infrared Spectroscopy with optodes placed over frontal, temporal, and parietal language regions. | at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits | |
Primary | Changes in amplitude of mismatch negativity response during sound discrimination | Electroencephalography is measured over the scalp while participant listens to speech sounds with infrequent "oddball" stimuli. Amplitude of the P100 for all stimuli as well as amplitude of the mismatch negativity response (frequent minus infrequent response) as well as change in these metrics over development are tracked in all groups. | at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits | |
Primary | Changes in LENA vocalizations and conversational turns | LENA is a voice recording system and proprietary program that records a child's home language environment and quantifies number of sounds and words each child produces as well as complexity of home language environment via number of conversational turns between the child and parents. | at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits | |
Primary | Changes in hearing thresholds | Hearing thresholds in dB as assessed using Conditioned Play Audiometry (CPA) or Visual Reinforced Audiometry (VRA) dependent on child age and developmental ability. | at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits | |
Primary | Otoacoustic Emissions (OAEs) | Signals produced by excitation of hair cells in cochlea are measured for a range of frequencies. | At first study visit | |
Primary | Changes in tympanometric pressure profile in the inner ear | Wide Band Tympanometry is completed to measure variability in tympanometric pressure for left and right ears that may affect hearing profile. | at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits | |
Secondary | Sensory profile 2 Auditory Processing subtest | parent-report measure of child's behavioral responses to sounds in their environment | at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits | |
Secondary | Sensory Profile 2 Attentional subtest | parent-report measure of child's awareness of and responses to sensory cues in their environment. | at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05418049 -
Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge
|
Phase 2 | |
Enrolling by invitation |
NCT01364818 -
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
|
N/A | |
Completed |
NCT00965432 -
A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107
|
Phase 1 | |
Completed |
NCT01120626 -
Randomized Controlled Study of Donepezil in Fragile X Syndrome
|
Phase 2 | |
Completed |
NCT01204151 -
Teaching Math Skills to Individuals With Fragile X Syndrome
|
N/A | |
Active, not recruiting |
NCT00334971 -
Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women
|
N/A | |
Enrolling by invitation |
NCT06139172 -
Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities
|
N/A | |
Recruiting |
NCT04977986 -
Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome
|
Phase 3 | |
Active, not recruiting |
NCT04698551 -
NIPD on cffDNA for Triplet Repeat Diseases
|
||
Completed |
NCT03722290 -
Metformin in Children and Adults With Fragile X Syndrome
|
Phase 2 | |
Completed |
NCT05030129 -
Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome
|
Phase 2 | |
Recruiting |
NCT04141163 -
Metformin in Patients With Fragile X
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Completed |
NCT00858689 -
Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome
|
N/A | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Enrolling by invitation |
NCT03802799 -
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
|
Phase 2/Phase 3 | |
Recruiting |
NCT05295277 -
Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort
|
||
Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
Completed |
NCT01725152 -
Ganaxolone Treatment in Children With Fragile X Syndrome
|
Phase 2 | |
Terminated |
NCT01433354 -
Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)
|
Phase 2/Phase 3 |